NCT05313815

Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer. Participants will receive external beam radiotherapy as a moderately hypofractionated boost to the prostate with pelvic radiation therapy. Androgen deprivation therapy will be prescribed at the discretion of the treating physician as per standard of care.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
RADIATION	Moderate hypofractionated boost to the prostate with pelvic RT (external beam radiotherapy)	External beam radiotherapy- 60 Gy in 20 fractions to the prostate, 48 Gy in 20 fractions to the pelvis, 68 Gy in 20 fraction optional boost to prostatic dominant intraprostatic lesion, 55 Gy in 20 fraction optional boost to involved pelvic lymph nodes

Timeline

• Start date: 2022-07-18
• Primary completion: 2025-07-01
• Completion: 2030-07-01
• First posted: 2022-04-06
• Last updated: 2024-06-18

Locations

1 site across 1 country: Canada